Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion

Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in china

(2011) Fang Han et al.   ANNALS OF NEUROLOGY

Immunogenicity, Boostability, and Sustainability of the Immune Response after Vaccination against Influenza A Virus (H1N1) 2009 in a Healthy Population

(2011) Elisabeth Huijskens et al.   Clinical and Vaccine Immunology

Effect on Cellular and Humoral Immune Responses of the AS03 Adjuvant System in an A/H1N1/2009 Influenza Virus Vaccine Administered to Adults during Two Randomized Controlled Trials

(2011) François Roman et al.   Clinical and Vaccine Immunology

Effectiveness of an Adjuvanted Monovalent Vaccine Against the 2009 Pandemic Strain of Influenza A(H1N1)v in Stockholm County, Sweden

(2011) A. Ortqvist et al.   CLINICAL INFECTIOUS DISEASES

Influenza viral neuraminidase: the forgotten antigen

(2011) Bert E Johansson et al.   Expert Review of Vaccines

Immunogenicity and safety of a novel AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in adults in Japan

(2011) Hideyuki Ikematsu et al.   Human vaccines & immunotherapeutics

Rapid Immunization Against H5N1: A Randomized Trial Evaluating Homologous and Cross-Reactive Immune Responses to AS03A-Adjuvanted Vaccination in Adults

(2011) Benjamin Lasko et al.   JOURNAL OF INFECTIOUS DISEASES

Dose-Sparing H5N1 A/Indonesia/05/2005 Pre-pandemic Influenza Vaccine in Adults and Elderly Adults: A Phase III, Placebo-Controlled, Randomized Study

(2011) Joanne M. Langley et al.   JOURNAL OF INFECTIOUS DISEASES

Field Effectiveness of Pandemic and 2009-2010 Seasonal Vaccines against 2009-2010 A(H1N1) Influenza: Estimations from Surveillance Data in France

(2011) Camille Pelat et al.   PLoS One

Longevity of the protective immune response induced after vaccination with one or two doses of AS03A-adjuvanted split H5N1 vaccine in ferrets

(2011) Benoît Baras et al.   VACCINE

Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: Results of a randomised single heterologous booster dose study at 15 months

(2011) George Risi et al.   VACCINE

Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity

(2011) Sandra Morel et al.   VACCINE

Pandemic H1N1 vaccine requires the use of an adjuvant to protect against challenge in naïve ferrets

(2011) Benoît Baras et al.   VACCINE

Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents

(2011) J. Garcia-Sicilia et al.   VACCINE

Immune responses to influenza virus infection

(2011) J.H.C.M. Kreijtz et al.   VIRUS RESEARCH

Estimates of Pandemic Influenza Vaccine Effectiveness in Europe, 2009–2010: Results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) Multicentre Case-Control Study

(2011) Marta Valenciano et al.   PLOS MEDICINE

Enhancing effects of adjuvanted 2009 pandemic H1N1 influenza A vaccine on memory B-cell responses in HIV-infected individuals

(2010) Jason Ho et al.   AIDS

A Heterologous MF59-Adjuvanted H5N1 Prepandemic Influenza Booster Vaccine Induces a Robust, Cross-Reactive Immune Response in Adults and the Elderly

(2010) E. Fragapane et al.   Clinical and Vaccine Immunology

AS03A‐Adjuvanted Influenza A (H1N1) 2009 Vaccine for Adults up to 85 Years of Age

(2010) François Roman et al.   CLINICAL INFECTIOUS DISEASES

2009 Pandemic Influenza A (H1N1) Deaths among Children—United States, 2009–2010

(2010) Chad M. Cox et al.   CLINICAL INFECTIOUS DISEASES

Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine

(2010) Woolf T Walker et al.   Expert Review of Vaccines

Induction of Immunity to Human Immunodeficiency Virus Type-1 by Vaccination

(2010) M. Juliana McElrath et al.   IMMUNITY

Protective effect of single-dose adjuvanted pandemic influenza vaccine in children

(2010) P. G. Van Buynder et al.   Influenza and Other Respiratory Viruses

CDC Advisory Committee Recommends Nearly Universal Influenza Vaccination

(2010) Bridget M. Kuehn   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

H5N1 Influenza Vaccine Formulated with AS03A Induces Strong Cross-Reactive and Polyfunctional CD4 T-Cell Responses

(2010) Philippe Moris et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Safety and Cross‐Reactive Immunogenicity of Candidate AS03‐Adjuvanted Prepandemic H5N1 Influenza Vaccines: A Randomized Controlled Phase 1/2 Trial in Adults

(2010) Joanne M. Langley et al.   JOURNAL OF INFECTIOUS DISEASES

Age-Specific Effectiveness of an Oil-in-Water Adjuvanted Pandemic (H1N1) 2009 Vaccine Against Confirmed Infection in High Risk Groups in England

(2010) N. Andrews et al.   JOURNAL OF INFECTIOUS DISEASES

Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study

(2010) Elizabeth Miller et al.   LANCET

Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial

(2010) Karl G Nicholson et al.   LANCET INFECTIOUS DISEASES

Vaccines with MF59 Adjuvant Expand the Antibody Repertoire to Target Protective Sites of Pandemic Avian H5N1 Influenza Virus

(2010) S. Khurana et al.   Science Translational Medicine

Effectiveness of seasonal 2008–2009, 2009–2010 and pandemic vaccines, to prevent influenza hospitalizations during the autumn 2009 influenza pandemic wave in Castellón, Spain. A test-negative, hospital-based, case–control study

(2010) Joan Puig-Barberà et al.   VACCINE

An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers

(2010) Abdullah S. Madhun et al.   VACCINE

Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6–35 months

(2010) Alfonso Carmona et al.   VACCINE

Economic Appraisal of Ontario's Universal Influenza Immunization Program: A Cost-Utility Analysis

(2010) Beate Sander et al.   PLOS MEDICINE

Squalene: A natural triterpene for use in disease management and therapy

(2009) L. Harivardhan Reddy et al.   ADVANCED DRUG DELIVERY REVIEWS

Squalene synthase: a critical enzyme in the cholesterol biosynthesis pathway

(2009) R Do et al.   CLINICAL GENETICS

Biological and Pharmacological Activities of Squalene and Related Compounds: Potential Uses in Cosmetic Dermatology

(2009) Zih-Rou Huang et al.   MOLECULES

Response to a Monovalent 2009 Influenza A (H1N1) Vaccine

(2009) Michael E. Greenberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunogenicity and tolerability of an AS03A-adjuvanted prepandemic influenza vaccine: A phase III study in a large population of Asian adults

(2009) Daniel Wai-Sing Chu et al.   VACCINE

Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults

(2009) Tino F. Schwarz et al.   VACCINE

MF59-adjuvanted versus non-adjuvanted influenza vaccines: Integrated analysis from a large safety database

(2009) Michele Pellegrini et al.   VACCINE

Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: Preliminary report of an observer-blind, randomised trial

(2009) François Roman et al.   VACCINE

Priming with AS03A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: An open non-randomised extension of a double-blind randomised primary study

(2009) Isabel Leroux-Roels et al.   VACCINE

Vitamin E ingestion improves several immune functions in elderly men and women

(2008) Monica De la Fuente et al.   FREE RADICAL RESEARCH

Age-associated changes in immune and inflammatory responses: impact of vitamin E intervention

(2008) Dayong Wu et al.   JOURNAL OF LEUKOCYTE BIOLOGY

A Clinical Trial of a Whole-Virus H5N1 Vaccine Derived from Cell Culture

(2008) Hartmut J. Ehrlich et al.   NEW ENGLAND JOURNAL OF MEDICINE

Broad Clade 2 Cross-Reactive Immunity Induced by an Adjuvanted Clade 1 rH5N1 Pandemic Influenza Vaccine

(2008) Isabel Leroux-Roels et al.   PLoS One

Cross-Protection against Lethal H5N1 Challenge in Ferrets with an Adjuvanted Pandemic Influenza Vaccine

(2008) Benoît Baras et al.   PLoS One

Correlates of protection: Novel generations of influenza vaccines

(2008) Guus F. Rimmelzwaan et al.   VACCINE

Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial

(2008) Hans C. Rümke et al.   VACCINE

Safety of MF59™ adjuvant

(2008) Viola Schultze et al.   VACCINE